nach oben

Erschienen in:

15.04.2020 | Original Article

Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas

verfasst von: Joon Young Hur, Yeon Jeong Kim, Sang Eun Yoon, Dae-Soon Son, Woong-Yang Park, Seok Jin Kim, Donghyun Park, Won Seog Kim

Erschienen in: Annals of Hematology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Cell-free DNA (cfDNA) can be released from tumor cells during proliferation and apoptosis; thus, a fraction of the cfDNA in patients with cancer is tumor-derived. However, the prognostic value of cfDNA in aggressive non-Hodgkin lymphoma (NHL) has not been determined. Between March 2017 and April 2019, plasma cfDNA was obtained from 158 patients with aggressive NHL who were registered in a prospective Samsung Medical Center lymphoma cohort (diffuse large B cell lymphoma (DLBCL), n = 51; T cell lymphoma (TCL), n = 51; NK/T cell lymphoma (NKTCL), n = 56). The concentration of cfDNA was estimated in longitudinal samples collected from patients with NHL before and during various chemotherapy regimens. In pretreatment samples, the median cfDNA concentration of all patients with aggressive lymphoma was 13.7 ng/dl (range 1.7–1792), which was significantly higher than that of healthy volunteers (median 7.4 ng, range 3.7–14.4, p < 0.001), and advanced stages showed a higher cfDNA level than earlier stages. Multivariate analysis identified high cfDNA as an independent factor for event-free survival that predicted poor prognosis in DLBCL (hazard ratio [HR] = 5.33, 95% confidence interval [CI] = 1.72–16.52, p = 0.003) and TCL (HR = 2.82, 95% CI = 1.10–7.20, p = 0.030). NKTCL patients with a high level of cfDNA had worse overall survival (HR = 4.71, 95% CI = 1.09–20.35, p = 0.037) compared with those with a low level of cfDNA. In this study, our results suggest the usefulness of pretreatment cfDNA as a prognostic marker for patients with DLBCL, TCL, and NKTCL.

Nur mit Berechtigung zugänglich

Volik S, Alcaide M, Morin RD, Collins C (2016) Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res 14(10):898–908. https://doi.org/10.1158/1541-7786.Mcr-16-0044 CrossRefPubMed

Viller Tuxen I, Barlebo Ahlborn L, Mau-Soerensen M, Staal Rohrberg K, Cilius Nielsen F, Oestrup O, Westmose Yde C, Richter Vogelius I, Lassen U (2019) Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients. Br J Cancer 121:125–130. https://doi.org/10.1038/s41416-019-0491-9 CrossRefPubMedPubMedCentral

Corcoran RB, Chabner BA (2018) Application of cell-free DNA analysis to cancer treatment. N Engl J Med 379(18):1754–1765. https://doi.org/10.1056/NEJMra1706174 CrossRefPubMed

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37(3):646–650PubMed

Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, Harris AL, Wainscoat JS (2004) Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 90(6):1211–1215. https://doi.org/10.1038/sj.bjc.6601609 CrossRefPubMedPubMedCentral

Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, Tang YY, Ju SQ (2014) Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer 111(8):1482–1489. https://doi.org/10.1038/bjc.2014.470 CrossRefPubMedPubMedCentral

Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21(21):3902–3908. https://doi.org/10.1200/jco.2003.02.006 CrossRefPubMed

Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, Clark J, Denholm KA, Thway K, Gonzalez De Castro D, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS (2012) Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 7(11):e47020. https://doi.org/10.1371/journal.pone.0047020 CrossRefPubMedPubMedCentral

Jones K, Nourse JP, Keane C, Crooks P, Gottlieb D, Ritchie DS, Gill D, Gandhi MK (2012) Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol 87(3):258–265. https://doi.org/10.1002/ajh.22252 CrossRefPubMed

10.

Rossi D, Spina V, Bruscaggin A, Gaidano G (2019) Liquid biopsy in lymphoma. Haematologica 104(4):648–652. https://doi.org/10.3324/haematol.2018.206177 CrossRefPubMedPubMedCentral

11.

Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4(6):650–661. https://doi.org/10.1158/2159-8290.Cd-13-1014 CrossRefPubMedPubMedCentral

12.

Kim J-Y, Park D, Son D-S, Nam SJ, Kim SW, Jung HH, Kim YJ, Park G, Park W-Y, Lee JE, Park YH (2017) Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. Oncotarget 8(49):86423–86434. https://doi.org/10.18632/oncotarget.21198 CrossRefPubMedPubMedCentral

13.

Park G, Park JK, Son D-S, Shin S-H, Kim YJ, Jeon H-J, Lee J, Park W-Y, Lee KH, Park D (2018) Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. Sci Rep 8(1):11631. https://doi.org/10.1038/s41598-018-30100-w CrossRefPubMedPubMedCentral

14.

Herrera AF, Armand P (2017) Minimal residual disease assessment in lymphoma: methods and applications. J Clin Oncol 35(34):3877–3887. https://doi.org/10.1200/jco.2017.74.5281 CrossRefPubMedPubMedCentral

15.

Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Burwinkel B (2018) Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. Breast Cancer Res Treat 169(1):69–82. https://doi.org/10.1007/s10549-018-4666-5 CrossRefPubMed

16.

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC, Marais R (2018) Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer (Oxford, England : 1990) 88:1–9. https://doi.org/10.1016/j.ejca.2017.10.029 CrossRef

17.

Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS (2016) A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 17(3):389–400. https://doi.org/10.1016/s1470-2045(15)00533-1 CrossRefPubMed

18.

Aucamp J, Bronkhorst AJ, Badenhorst CPS, Pretorius PJ (2018) The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biol Rev Camb Philos Soc 93(3):1649–1683. https://doi.org/10.1111/brv.12413 CrossRefPubMed

19.

Li M, Jia Y, Xu J, Cheng X, Xu C (2017) Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience. Ann Hematol 96(8):1343–1351. https://doi.org/10.1007/s00277-017-3043-5 CrossRefPubMedPubMedCentral

20.

Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alo F, Martini M, Larocca LM, Voso MT, Leone G (2009) Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol 20(8):1408–1413. https://doi.org/10.1093/annonc/mdp006 CrossRefPubMed

21.

Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M (2014) C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 111:55–60. https://doi.org/10.1038/bjc.2014.277 CrossRefPubMedPubMedCentral

22.

Ochi Y, Koba Y, Shimomura Y, Ono Y, Hiramoto N, Yoshioka S, Tabata S, Yonetani N, Matsushita A, Hashimoto H, Imai Y, Ishikawa T (2015) The significance of serum albumin level and platelet count in patients with diffuse large b-cell lymphoma in the context of an enhanced International Prognostic Index (NCCN-IPI). Blood 126(23):1463–1463CrossRef

23.

Okada K, Ochi S, Nagayama T, Nabe S, Sakai K, Muranushi H, Okamoto Y, Sugiura H, Sato A, Sato T, Maeda T, Onishi T, Ueda Y (2014) Absolute lymphocyte count as an independent prognostic factor of IPI and NCCN-IPI in DLBCL patients. Blood 124(21):1636–1636CrossRef

24.

Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 81(6):448–453. https://doi.org/10.1111/j.1600-0609.2008.01129.x CrossRefPubMed

25.

Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK (2007) Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 21:2227–2230. https://doi.org/10.1038/sj.leu.2404780 https://www.nature.com/articles/2404780#supplementary-information CrossRefPubMed

26.

Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, Baldini L, Brugiatelli M, Federico M, Polliack A (2014) Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica 99(1):125–130. https://doi.org/10.3324/haematol.2013.088161 CrossRefPubMedPubMedCentral

27.

Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, Matovina-Brko G, Hajder J, Matkovic T, Zivkovic R, Stanisavljevic N, Todorovic M, Petrovic D, Mihaljevic B (2014) Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med 25(3):296–302. https://doi.org/10.1016/j.ejim.2014.01.019 CrossRefPubMed

28.

Zhou SJ, Ma YY, Zhang Y, Luo S, Tang LY, Chen Y, Sun L, Yu K (2017) Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. Ann Hematol 96(2):237–243. https://doi.org/10.1007/s00277-016-2865-x CrossRefPubMed

29.

Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Call TG, Porrata LF (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134(6):596–601. https://doi.org/10.1111/j.1365-2141.2006.06232.x CrossRefPubMed

30.

Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22(1):149–155. https://doi.org/10.1093/annonc/mdq314 CrossRefPubMed

31.

Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN (2012) Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol 157(3):321–330. https://doi.org/10.1111/j.1365-2141.2012.09067.x CrossRefPubMed

32.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Duhrsen U, Huttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA (2018) Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 36(28):2845–2853. https://doi.org/10.1200/jco.2018.78.5246 CrossRefPubMedPubMedCentral

Titel: Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas
verfasst von: Joon Young Hur
Yeon Jeong Kim
Sang Eun Yoon
Dae-Soon Son
Woong-Yang Park
Seok Jin Kim
Donghyun Park
Won Seog Kim
Publikationsdatum: 15.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 6/2020
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04008-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century

The concomitance of lymphoma and breast carcinoma in the bone

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

Management of myelofibrosis after ruxolitinib failure

Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy